Literature DB >> 9602586

Reduced quality of clot formation with gelatin-based plasma substitutes.

S N Mardel1, F M Saunders, H Allen, G Menezes, C M Edwards, L Ollerenshaw, D Baddeley, A Kennedy, R M Ibbotson.   

Abstract

We have studied, over a wide range of dilutions using techniques of clot weight, thrombelastography and scanning electron microscopy, the physical properties of a blood clot formed in vitro when fresh blood was diluted with gelatin-based colloid solutions compared with crystalloid controls. The colloid solutions tested (3.5% polygeline (Haemaccel) and 4% succinylated gelatin (Gelofusine)) produced clots that had reduced median weight (P < 0.001 and P = 0.018, respectively) and reduced mean shear modulus (P < 0.001) compared with crystalloid controls. Scanning electron microscopy showed that the fibrin formed a less extensive mesh in the presence of the gelatin-based colloids compared with crystalloid. Reduction in clot quality with gelatin-based colloids has not been noted previously and further work is needed to ascertain if this occurs in vivo as these solutions are used frequently in patients who require full haemostatic competence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9602586     DOI: 10.1093/bja/80.2.204

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  17 in total

Review 1.  [Treatment of hemorrhagic shock. New therapy options].

Authors:  W G Voelckel; A von Goedecke; D Fries; A C Krismer; V Wenzel; K H Lindner
Journal:  Anaesthesist       Date:  2004-12       Impact factor: 1.041

2.  The effects of commonly used resuscitation fluids on whole blood coagulation.

Authors:  T J Coats; E Brazil; M Heron
Journal:  Emerg Med J       Date:  2006-07       Impact factor: 2.740

3.  Three-dimensional quantitative phase imaging of blood coagulation structures by optical projection tomography in flow cytometry using digital holographic microscopy.

Authors:  Hideki Funamizu; Yoshihisa Aizu
Journal:  J Biomed Opt       Date:  2018-10       Impact factor: 3.170

Review 4.  The pathophysiology, diagnosis and treatment of the acute coagulopathy of trauma and shock: a literature review.

Authors:  J Kaczynski; M Wilczynska; L Fligelstone; J Hilton
Journal:  Eur J Trauma Emerg Surg       Date:  2013-12-12       Impact factor: 3.693

5.  A calcium-containing electrolyte-balanced hydroxyethyl starch (HES) solution is associated with higher factor VIII activity than is a non-balanced HES solution, but does not affect von Willebrand factor function or thromboelastometric measurements--results of a model of in vitro haemodilution.

Authors:  Juliane Rau; Christoph Rosenthal; Elisabeth Langer; Michael Sander; Erika Schulte; Michael Schuster; Christian von Heymann
Journal:  Blood Transfus       Date:  2013-11-15       Impact factor: 3.443

Review 6.  [Management of coagulation after multiple trauma].

Authors:  D Fries; T Haas; V Salchner; K Lindner; P Innerhofer
Journal:  Anaesthesist       Date:  2005-02       Impact factor: 1.041

Review 7.  Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.

Authors:  Michael Joannidis; Wilfred Druml; Lui G Forni; A B Johan Groeneveld; Patrick Honore; Heleen M Oudemans-van Straaten; Claudio Ronco; Marie R C Schetz; Arend Jan Woittiez
Journal:  Intensive Care Med       Date:  2010-03       Impact factor: 17.440

8.  Does calcium cause the different effects of Gelofusine and Haemaccel on coagulation?

Authors:  T J Coats; M Heron
Journal:  Emerg Med J       Date:  2006-03       Impact factor: 2.740

Review 9.  [Fluid resuscitation in hemorrhage].

Authors:  M Roessler; K Bode; M Bauer
Journal:  Anaesthesist       Date:  2014-10       Impact factor: 1.041

10.  Effects of fibrinogen concentrate after shock/resuscitation: a comparison between in vivo microvascular clot formation and thromboelastometry*.

Authors:  Judith Martini; Pedro Cabrales; Dietmar Fries; Marcos Intaglietta; Amy G Tsai
Journal:  Crit Care Med       Date:  2013-11       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.